# SCHOLAR-2 (NCT04680442)

> Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

No report yet. It can be ordered.

- Drugs tested: trastuzumab; pertuzumab; trastuzumab emtansine
- Indication: breast cancer with overt left ventricular dysfunction

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04680442
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Population Health Research Institute
- Conditions: Breast Cancer; Heart Failure
- Interventions: Trastuzumab; Pertuzumab; Trastuzumab emtansine
- Enrollment: 130
- Primary outcome: primary efficacy outcome
- Primary outcome: co-primary safety outcomes

## Indexed commentary on SCHOLAR-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 15 posts on X
- 1 podcast episode

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=scholar-2-nct04680442

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04680442", "email": "<work email>"}; the inbox owner confirms by the emailed link.